FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 01/2024 published”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the US-Biotech sector.
As of the top of January 2024 we establish the next present VC developments in america:
- In January, general Life Sciences funding has reached EUR 2,239m
- Biotechreceived 60% of the full funding quantity (EUR 1,336m)
- Oncology dominates as the highest indicationinBiotech
- Cellanome has the very best transaction quantity of EUR 137m in January, adopted by Eyconis with EUR 137m and Sudo Biosciences with EUR 135m
- Premji Make investments (United States) is essentially the most dominant investor (by deal quantity), adopted by Novo Holdings (Denmark) and Venrock (United States)
- In comparison with January 2023, funding quantity in Jan 2024 within the US is lagging behind vs final 12 months (EUR 2,239m vs EUR 3,330m), displaying a slower begin compared to Europe
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink.